RIP3/MLKL pathway-regulated necroptosis: A new mechanism of paclitaxel-induced peripheral neuropathy

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Paclitaxel (PTX) chemotherapy commonly induces peripheral neuropathy (PIPN), a painful condition often resistant to treatment.
• PIPN is characterized by cell death and neuroinflammation, with necroptosis—a regulated necrotic cell death pathway involving RIP3 and MLKL—implicated in neurodegeneration but not yet in PIPN.

Purpose of the Study:

• To investigate the role of necroptosis in the development of Paclitaxel-induced peripheral neuropathy (PIPN).
• To evaluate the therapeutic potential of necroptosis inhibitors in managing PIPN.

Main Methods:

• Rats were administered Paclitaxel (PTX) to induce PIPN.
• The study utilized necrostatin-1 (Nec-1), a necroptosis antagonist, to assess its effects on PTX-induced neuropathy.
• Changes in pain behavior, cell necrosis, pro-inflammatory cytokines, RIP3, MLKL, and glial fibrillary acidic protein (GFAP) in the dorsal root ganglion (DRG) were measured.

Main Results:

• PTX administration induced significant hyperalgesia and allodynia in rats.
• PTX treatment led to increased cell necrosis, pro-inflammatory cytokines, RIP3, and MLKL protein levels in the DRG, primarily in neurons.
• Activation of satellite glial cells (SGCs), indicated by GFAP upregulation, was also observed following PTX treatment.
• Nec-1 administration successfully prevented PTX-induced pain behaviors, cell necrosis, and neuroinflammation.

Conclusions:

• Neuronal necroptosis, mediated by the RIP3/MLKL pathway, plays a significant role in the pathogenesis of PIPN.
• Blocking necroptosis with Nec-1 offers a potential therapeutic strategy for managing Paclitaxel-induced neuropathic pain.